The Journal of Nutritional Biochemistry
Volume 15, Issue 9 , Pages 506-516 , September 2004

Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases

  • Orly Weinreb

      Affiliations

    • Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion-Faculty of Medicine, 31096 Haifa, Israel
    • ,
  • Silvia Mandel

      Affiliations

    • Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion-Faculty of Medicine, 31096 Haifa, Israel
    • ,
  • Tamar Amit

      Affiliations

    • Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion-Faculty of Medicine, 31096 Haifa, Israel
    • ,
  • Moussa B.H. Youdim

      Affiliations

    • Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion-Faculty of Medicine, 31096 Haifa, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972-4-8295290; fax: +972-4-8513145

Received 8 March 2004 ,Revised 10 May 2004 ,Accepted 26 May 2004.

References 

  1. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V. Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr Biochem. 2002;13:444–461
  2. van Acker SA, van den Berg DJ, Tromp MN, Griffioen DH, van Bennekom WP, van der Vijgh WJ, et al. Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med. 1996;20:331–342
  3. Gotz ME, Kunig G, Riederer P, Youdim MB. Oxidative stress (free radical production in neural degeneration). Pharmacol Ther. 1994;63:37–122
  4. Halliwell B. Role of free radicals in the neurodegenerative diseases (therapeutic implications for antioxidant treatment). Drugs Aging. 2001;18:685–716
  5. Gotz ME, Freyberger A, Riederer P. Oxidative stress (a role in the pathogenesis of Parkinson's disease). J Neural Transm. 1990;29(Suppl):241–249
  6. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609–1623
  7. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 1989;52:515–520
  8. Linazasoro G. Neuroprotection in Parkinson's disease (love story or mission impossible?). Expert Rev Neurotherapeutics. 2002;2:403–416
  9. Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. J Biomed Biotechnol. 2002;2:120–123
  10. Perry G, Taddeo MA, Nunomura A, Zhu X, Zenteno-Savin T, Drew KL, et al. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases (beyond damage and response). Comp Biochem Physiol C Toxicol Pharmacol. 2002;133:507–513
  11. Hellenbrand W, Seidler A, Boeing H, Robra BP, Vieregge P, Nischan P, et al. Diet and Parkinson's disease. I (A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study). Neurology. 1996;47:636–643
  12. Higdon JV, Frei B. Tea catechins and polyphenols (health effects, metabolism, and antioxidant functions). Crit Rev Food Sci Nutr. 2003;43:89–143
  13. Wiseman SA, Balentine DA, Frei B. Antioxidants in tea. Crit Rev Food Sci Nutr. 1997;37:705–718
  14. Slikker W, Youdim MB, Palmer GC, Hall E, Williams C, Trembly B. The future of neuroprotection. Ann NY Acad Sci. 1999;890:529–533
  15. Salah N, Miller NJ, Paganga G, Tijburg L, Bolwell GP, Rice-Evans C. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophys. 1995;322:339–346
  16. Nanjo F, Goto K, Seto R, Suzuki M, Sakai M, Hara Y. Scavenging effects of tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med. 1996;21:895–902
  17. Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med. 2001;30:433–446
  18. Schroeter H, Boyd C, Spencer JP, Williams RJ, Cadenas E, Rice-Evans C. MAPK signaling in neurodegeneration (influences of flavonoids and of nitric oxide). Neurobiol Aging. 2002;23:861–880
  19. Levites Y, Amit T, Mandel S, Youdim MBH. Neuroprotection and neurorescue against amyloid beta toxicity and PKC-dependent release of non-amyloidogenic soluble precusor protein by green tea polyphenol (−)-epigallocatechin-3-gallate. FASEB J. 2003;17:952–954
  20. Levites Y, Weinreb O, Maor G, Youdim MBH, Mandel S. Green tea polyphenol (−)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem. 2001;78:1073–1082
  21. Chen C, Yu R, Owuor ED, Kong AN. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res. 2000;23:605–612
  22. Levites Y, Amit T, Youdim MBH, Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (−)-epigallocatechin-3-gallate neuroprotective action. J Biol Chem. 2002;277:30574–30580
  23. Hollman PC, Feskens EJ, Katan MB. Tea flavonols in cardiovascular disease and cancer epidemiology. Proc Soc Exp Biol Med. 1999;220:198–202
  24. Yang F, de Villiers WJ, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J Nutr. 1998;128:2334–2340
  25. Tedeschi E, Menegazzi M, Yao Y, Suzuki H, Forstermann U, Kleinert H. Green tea inhibits human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1alpha activation. Mol Pharmacol. 2004;65:111–120
  26. Weisburger JH, Chung FL. Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols. Food Chem Toxicol. 2002;40:1145–1154
  27. Pannala AS, Rice-Evans CA, Halliwell B, Singh S. Inhibition of peroxynitrite-mediated tyrosine nitration by catechin polyphenols. Biochem Biophys Res Commun. 1997;232:164–168
  28. Nanjo F, Mori M, Goto K, Hara Y. Radical scavenging activity of tea catechins and their related compounds. Biosci Biotechnol Biochem. 1999;63:1621–1623
  29. Khokhar S, Magnusdottir SG. Total phenol, catechin, and caffeine contents of teas commonly consumed in the United Kingdom. J Agric Food Chem. 2002;50:565–570
  30. Pietta PG, Simonetti P, Gardana C, Brusamolino A, Morazzoni P, Bombardelli E. Catechin metabolites after intake of green tea infusions. Biofactors. 1998;8:111–118
  31. Lee MJ, Wang ZY, Li H, Chen L, Sun Y, Gobbo S, et al. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev. 1995;4:393–399
  32. Harada M, Kan Y, Naoki H, Fukui Y, Kageyama N, Nakai M, et al. Identification of the major antioxidative metabolites in biological fluids of the rat with ingested (+)-catechin and (−)-epicatechin. Biosci Biotechnol Biochem. 1999;63:973–977
  33. Nakagawa K, Okuda S, Miyazawa T. Dose-dependent incorporation of tea catechins, (−)-epigallocatechin-3-gallate and (−)-epigallocatechin, into human plasma. Biosci Biotechnol Biochem. 1997;61:1981–1985
  34. Yang CS, Kim S, Yang GY, Lee MJ, Liao J, Chung JY, et al. Inhibition of carcinogenesis by tea (bioavailability of tea polyphenols and mechanisms of actions). Proc Soc Exp Biol Med. 1999;220:213–217
  35. Hong JT, Ryu SR, Kim HJ, Lee JK, Lee SH, Kim DB, et al. Neuroprotective effect of green tea extract in experimental ischemia-reperfusion brain injury. Brain Res Bull. 2000;53:743–749
  36. Abd El Mohsen MM, Kuhnle G, Rechner AR, Schroeter H, Rose S, Jenner P, et al. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med. 2002;33:1693–1702
  37. Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H. Wide distribution of [3H](−)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis. 1998;19:1771–1776
  38. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol. 2002;155:732–738
  39. Tan EK, Tan C, Fook-Chong SM, Lum SY, Chai A, Chung H, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease (a study in ethnic Chinese). J Neurol Sci. 2003;216:163–167
  40. Li SC, Schoenberg BS, Wang CC, Cheng XM, Rui DY, Bolis CL, et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol. 1985;42:655–657
  41. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease (an updated review). Neuroepidemiology. 1993;12:195–208
  42. Le Bars PL, Velasco FM, Ferguson JM, Dessain EC, Kieser M, Hoerr R. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology. 2002;45:19–26
  43. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, et al. Wine consumption and dementia in the elderly (a prospective community study in the Bordeaux area). Rev Neurol (Paris). 1997;153:185–192
  44. Guo Q, Zhao B, Li M, Shen S, Xin W. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta. 1996;1304:210–222
  45. Grunblatt E, Mandel S, Maor G, Youdim MBH. Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal doamine neuronal loss. J Neurochem. 2001;77:146–156
  46. Grunblatt E, Mandel S, Berkuzki T, Youdim MBH. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord. 1999;14:612–618
  47. Pan T, Fei J, Zhou X, Jankovic J, Le W. Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury. Life Sci. 2003;72:1073–1083
  48. Lu H, Meng X, Yang CS. Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (−)-epigallocatechin gallate. Drug Metab Dispos. 2003;31:572–579
  49. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41:261–309
  50. Monteiro HP, Winterbourn CC. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol. 1989;38:4177–4182
  51. Mochizuki H, Imai H, Endo K, Yokomizo K, Murata Y, Hattori N, et al. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett. 1994;168:251–253
  52. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra (a histochemical and neurochemical study). Brain Res. 1994;660:8–18
  53. Temlett JA, Landsberg JP, Watt F, Grime GW. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey (evidence from proton microprobe elemental microanalysis). J Neurochem. 1994;62:134–146
  54. Senior K. New genes reveal major role for iron in neurodegeneration. Lancet. 2001;358:302
  55. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci. 2003;26:207–214
  56. Checler F. Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem. 1995;65:1431–1444
  57. Nunan J, Small DH. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett. 2000;483:6–10
  58. Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh MH, et al. The green tea polyphenol (−)-epigallocatechin gallate attenuates beta- amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci. 2001;70:603–614
  59. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro (implications for the prevention and therapeutics of Alzheimer's disease). J Neurochem. 2003;87:172–181
  60. Mills J, Reiner PB. Regulation of amyloid precursor protein cleavage. J Neurochem. 1999;72:443–460
  61. Slack BE, Nitsch RM, Livneh E, Kunz GM, Breu J, Eldar H, et al. Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase C alpha. J Biol Chem. 1993;268:21097–21101
  62. Benussi L, Govoni S, Gasparini L, Binetti G, Trabucchi M, Bianchetti A, et al. Specific role for protein kinase C alpha in the constitutive and regulated secretion of amyloid precursor protein in human skin fibroblasts. Neurosci Lett. 1998;240:97–101
  63. Matsushima H, Shimohama S, Chachin M, Taniguchi T, Kimura J. Ca2+-dependent and Ca2+-independent protein kinase C changes in the brain of patients with Alzheimer's disease. J Neurochem. 1996;67:317–323
  64. Morel I, Lescoat G, Cogrel P, Sergent O, Pasdeloup N, Brissot P, et al. Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem Pharmacol. 1999;45:13–19
  65. Jeong JH, Kim HJ, Lee TJ, Kim MK, Park ES, Choi BS. Epigallocatechin 3-gallate attenuates neuronal damage induced by 3-hydroxykynurenine. Toxicology. 2004;195:53–60
  66. Levites Y, Youdim MBH, Maor G, Mandel S. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol. 2002;63:21–29
  67. Higuchi A, Yonemitsu K, Koreeda A, Tsunenari S. Inhibitory activity of epigallocatechin gallate (EGCg) in paraquat-induced microsomal lipid peroxidation—a mechanism of protective effects of EGCg against paraquat toxicity. Toxicology. 2003;183:143–149
  68. Liou HH, Chen RC, Chen TH, Tsai YF, Tsai MC. Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (−)-deprenyl in vivo. Toxicol Appl Pharmacol. 2001;172:37–43
  69. Thompson M, Williams CR, Elliot GE. Stability of flavonoid complexes of copper(II) and flavonoid antioxidant activity. Anal Chim Acta. 1976;85:375–381
  70. Grinberg LN, Newmark H, Kitrossky N, Rahamim E, Chevion M, Rachmilewitz EA. Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem Pharmacol. 1997;54:973–978
  71. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect. 1990;2:327–340
  72. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem. 1991;56:978–982
  73. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165:208–210
  74. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. 1995;202:17–20
  75. McGeer PL, McGeer EG. The inflammatory response system of brain (implications for therapy of Alzheimer and other neurodegenerative diseases). Brain Res Brain Res Rev. 1995;21:195–218
  76. Sakaguchi S, Furusawa S, Yokota K, Sasaki K, Takayanagi M, Takayanagi Y. The enhancing effect of tumour necrosis factor-alpha on oxidative stress in endotoxemia. Pharmacol Toxicol. 1996;79:259–265
  77. Lin YL, Lin JK. (−)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol. 1997;52:465–472
  78. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991;10:2247–2258
  79. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci USA. 1997;94:7531–7536
  80. Lin YL, Tsai SH, Lin-Shiau SY, Ho CT, Lin JK. Theaflavin-3,3′-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-kappaB in macrophages. Eur J Pharmacol. 1999;367:379–388
  81. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326–1331
  82. Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci. 1999;19:2455–2463
  83. Cordey M, Gundimeda U, Gopalakrishna R, Pike CJ. Estrogen activates protein kinase C in neurons (role in neuroprotection). J Neurochem. 2003;84:1340–1348
  84. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000;10:381–391
  85. Koh SH, Kim SH, Kwon H, Park Y, Kim KS, Song CW, et al. Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress–induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res Mol Brain Res. 2003;118:72–81
  86. Mandel S, Reznichenko L, Amit T, Youdim M. Green tea polyphenol (−)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway. Neurotoxocity Research. 2003;5:419–424
  87. Vaudry D, Stork PJ, Lazarovici P, Eiden LE. Signaling pathways for PC12 cell differentiation (making the right connections). Science. 2002;296:1648–1649
  88. Harris CA, Deshmukh M, Tsui-Pierchala B, Maroney AC, Johnson EM. Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. J Neurosci. 2002;22:103–113
  89. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911–1912
  90. Owuor ED, Kong AN. Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol. 2002;64:765–770
  91. Satoh T, Nakatsuka D, Watanabe Y, Nagata I, Kikuchi H, Namura S. Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett. 2000;288:163–166
  92. Schroeter H, Spencer JP, Rice-Evans C, Williams RJ. Flavonoids protect neurons from oxidized low-density-lipoprotein–induced apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and caspase-3. Biochem J. 2001;358:547–557
  93. Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol. 2000;279:L429–L438
  94. Maher P. How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J Neurosci. 2001;21:2929–2938
  95. Cardell M, Wieloch T. Time course of the translocation and inhibition of protein kinase C during complete cerebral ischemia in the rat. J Neurochem. 1993;61:1308–1314
  96. Busto R, Globus MY, Neary JT, Ginsberg MD. Regional alterations of protein kinase C activity following transient cerebral ischemia (effects of intraischemic brain temperature modulation). J Neurochem. 1994;63:1095–1103
  97. Nishino N, Kitamura N, Nakai T, Hashimoto T, Tanaka C. Phorbol ester binding sites in human brain (characterization, regional distribution, age-correlation, and alterations in Parkinson's disease). J Mol Neurosci. 1989;1:19–26
  98. Gubina E, Rinaudo MS, Szallasi Z, Blumberg PM, Mufson RA. Overexpression of protein kinase C isoform epsilon but not delta in human interleukin-3-dependent cells suppresses apoptosis and induces bcl-2 expression. Blood. 1998;91:823–829
  99. Whelan RD, Parker PJ. Loss of protein kinase C function induces an apoptotic response. Oncogene. 1998;16:1939–1944
  100. Ruvolo PP, Deng X, Carr BK, May WS. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem. 1998;273:25436–25442
  101. Chung JH, Han JH, Hwang EJ, Seo JY, Cho KH, Kim KH, Youn JI, Eun HC. Dual mechanisms of green tea extract-induced cell survival in human epidermal keratinocytes. FASEB J 2003;17:1913–5
  102. Sah JF, Balasubramanian S, Eckert RL, Rorke EA. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway: evidence for direct inhibition of ERK1/2 and Akt kinases. J Biol Chem 2004;279:12755–62
  103. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate–induced apoptosis of LNCaP cells. Oncogene. 2003;22:4851–4859
  104. Halliwell B. Vitamin C (antioxidant or pro-oxidant in vivo?). Free Radi Res. 1996;25:439–454
  105. Gassen M, Gross A, Youdim MB. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord. 1998;13:242–248
  106. Mandel S, Grunblatt E, Maor G, Youdim MBH. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res. 2002;27:1231–1243
  107. Weinreb O, Mandel S, Youdim MB. Gene and protein expression profiles of anti- and pro-apoptotic actions of dopamine, R-apomorphine, green tea polyphenol (−)-epigallocatechine-3-gallate and melatonin. Ann NY Acad Sci 2003;993:351–61, discussion 87–93
  108. Weinreb O, Mandel S, Youdim MBH. CDNA gene expression profile homology of antioxidants and their anti-apoptotic and pro-apoptotic activities in human neuroblastoma cells. FASEB J. 2003;17:935–937
  109. Gassen M, Youdim MBH. Free radical scavengers (chemical concepts and clinical relevance). J Neural Transm. 1999;56(Suppl):193–210
  110. Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MBH. Neuroprotective strategies in Parkinson's disease (an update on progress). CNS Drugs. 2003;17:729–762
  111. Maruyama W, Takahashi T, Youdim MBH, Naoi M. The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm. 2002;109:467–481
  112. Maruyama W, Akao Y, Youdim MBH, Boulton AA, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem. 2001;78:727–735
  113. Bates TE, Heales SJ, Davies SE, Boakye P, Clark JB. Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria (evidence for a primary involvement of energy depletion). J Neurochem. 1994;63:640–648
  114. Kalivendi SV, Cunningham S, Kotamraju S, Joseph J, Hillard CJ, Kalyanaraman B. a-Synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J Biol Chem 2004;279:15240–7
  115. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem. 2002;277:45518–45528

PII: S0955-2863(04)00118-4

doi: 10.1016/j.jnutbio.2004.05.002

The Journal of Nutritional Biochemistry
Volume 15, Issue 9 , Pages 506-516 , September 2004

Article Tools

* Image Usage & Resolution